---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-015501"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:48:28.003839+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Terns Pharmaceuticals CFO Mark Vignola Departs; CEO Burroughs Takes Interim CFO Role

## Summary
- CFO Mark Vignola separated effective Feb 1, 2025; entered consulting agreement through July 2025.
- CEO Amy Burroughs assumes principal financial officer; VP Finance David Strauss named principal accounting officer, each on interim basis.
- Vignola receives $30k/month for first two months, $15k/month for next two, then hourly; equity awards continue vesting.
- Departure not due to any disagreement with company operations, policies, or practices.

## SEC filing metadata
- accession: 0000950170-25-015501
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017025015501/0000950170-25-015501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017025015501/tern-20250201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-015501
- JSON: https://secwatch.observer/filing/0000950170-25-015501.json
- Plain text: https://secwatch.observer/filing/0000950170-25-015501.txt

## Source-grounded claims
- claim_id: bef32ff8d4
  claim: Amy Burroughs changed role as Principal Financial Officer at Terns Pharmaceuticals, Inc..
  evidence_excerpt: Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025015501/0000950170-25-015501-index.htm
- claim_id: ca537816dc
  claim: Mark Vignola resigned as Chief Financial Officer at Terns Pharmaceuticals, Inc..
  evidence_excerpt: On February 1, 2025, pursuant to, and subject to the terms of, the Vignola Transition Agreement, Mr. Vignola confirmed that his separation from employment was effective as of February 1, 2025 (the “Vignola Separation Date”) and resigned as of the Vignola Separation Date from all officer and director positions at the Company, the Subsidiary and any other subsidiary or affiliate.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025015501/0000950170-25-015501-index.htm
- claim_id: e6fb8af689
  claim: David Strauss changed role as Principal Accounting Officer at Terns Pharmaceuticals, Inc..
  evidence_excerpt: Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025015501/0000950170-25-015501-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.